Inventiva (IVA)

Executive Summary

Inventiva is a clinical-stage French biopharmaceutical company developing innovative oral small molecules targeting fibrotic diseases, lysosomal storage disorders, and oncology. Its lead asset, lanifibranor, is a pan-PPAR agonist in Phase III development for NASH/MASH and has received FDA Breakthrough Therapy designation. The company's Phase III NATiV3 trial (NCT04849728) is evaluating lanifibranor in NASH patients and is expected to complete in September 2026. Positive data could position lanifibranor as a first-in-class treatment for NASH, a large unmet medical need with no approved therapies. Inventiva also has early-stage programs in systemic sclerosis and mucopolysaccharidosis VI, though these are less advanced.

Upcoming Catalysts (preview)

• Q4 2026Phase III NATiV3 top-line data for lanifibranor in NASH55% success
• 2027Potential FDA submission for lanifibranor in NASH40% success
• TBDPhase II data update for odiparcil in MPS VI30% success